Allergic Rhinitis, Asthma and COPD Therapeutics Practice Test

The choice of salmeterol/fluticasone as a combination therapy in asthma treatment is grounded in its dual purpose of providing both a long-acting bronchodilator and an inhaled corticosteroid. Salmeterol, a long-acting beta-agonist, works by relaxing the muscles around the airways, thereby improving airflow and easing breathing over an extended period. Fluticasone, on the other hand, is an inhaled corticosteroid that reduces inflammation within the airways, addressing the underlying inflammatory component that is characteristic of asthma.

This combination is particularly effective because it offers both immediate relief from bronchoconstriction through the bronchodilator and long-term control of inflammation and asthma symptoms, which is essential for preventing exacerbations. This makes salmeterol/fluticasone a preferred option in many treatment plans for patients with persistent asthma.

Other medications listed, such as montelukast, beclomethasone, and albuterol, play important roles in asthma management. Montelukast is a leukotriene receptor antagonist used in some patients, particularly those with allergic rhinitis. Beclomethasone is an inhaled corticosteroid but is not typically combined with another active ingredient in a single inhaler like sal